| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 10587643 | Bioorganic & Medicinal Chemistry Letters | 2013 | 5 Pages | 
Abstract
												AAC(6â²)-Ib is an important aminoglycoside resistance enzyme to target with enzymatic inhibitors. An in silico screening approach was used to identify potential inhibitors from the ChemBridge library. Several compounds were identified, of which two of them, 4-[(2-{[1-(3-methylphenyl)-4,6-dioxo-2-thioxotetrahydro-5(2H)-pyrimidinylidene]methyl}phenoxy)methyl]benzoic acid and 2-{5-[(4,6-dioxo-1,3-diphenyl-2-thioxotetrahydro-5(2H)-pyrimidinylidene)methyl]-2-furyl}benzoic acid, showed micromolar activity in inhibiting acetylation of kanamycin A. These compounds are predicted to bind the aminoglycoside binding site of AAC(6â²)-Ib and exhibited competitive inhibition against kanamycin A.
											Keywords
												
											Related Topics
												
													Physical Sciences and Engineering
													Chemistry
													Organic Chemistry
												
											Authors
												David L. Lin, Tung Tran, Christina Adams, Jamal Y. Alam, Steven R. Herron, Marcelo E. Tolmasky, 
											![First Page Preview: Inhibitors of the aminoglycoside 6â²-N-acetyltransferase type Ib [AAC(6â²)-Ib] identified by in silico molecular docking Inhibitors of the aminoglycoside 6â²-N-acetyltransferase type Ib [AAC(6â²)-Ib] identified by in silico molecular docking](/preview/png/10587643.png)